{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:46:06Z","timestamp":1790754366069,"version":"4.1.0"},"reference-count":57,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003185","name":"Fraunhofer-Gesellschaft","doi-asserted-by":"publisher","award":["Fraunhofer Cluster of Immune Mediated Diseases (CI"],"award-info":[{"award-number":["Fraunhofer Cluster of Immune Mediated Diseases (CI"]}],"id":[{"id":"10.13039\/501100003185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,9,18]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>Autoimmune disorders occur when immune cells go wrong and attack the body\u2019s own tissues. Currently, autoimmune disorders are largely treated by broad immunosuppressive agents and blocking antibodies, which can manage the diseases but often are not curative. Thus, there is an urgent need for advanced therapies for patients suffering from severe and refractory autoimmune diseases, and researchers have considered cell therapy as potentially curative approach for several decades. In the wake of its success in cancer therapy, adoptive transfer of engineered T cells modified with chimeric antigen receptors (CAR) for target recognition could now become a therapeutic option for some autoimmune diseases. Here, we review the ongoing developments with CAR T cells in the field of autoimmune disorders. We will cover first clinical results of applying anti-CD19 and anti-B cell maturation antigen CAR T cells for B cell elimination in systemic lupus erythematosus, refractory antisynthetase syndrome and myasthenia gravis, respectively. Furthermore, in preclinical models, researchers have also developed chimeric autoantibody receptor T cells that can eliminate individual B cell clones producing specific autoantibodies, and regulatory CAR T cells that do not eliminate autoreactive immune cells but dampen their wrong activation. Finally, we will address safety and manufacturing aspects for CAR T cells and discuss mRNA technologies and automation concepts for ensuring the future availability of safe and efficient CAR T cell products.<\/jats:p>","DOI":"10.1136\/rmdopen-2022-002907","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T12:41:02Z","timestamp":1700743262000},"page":"e002907","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":94,"title":["CAR T cells for treating autoimmune diseases"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4233-2268","authenticated-orcid":false,"given":"Ulrich","family":"Blache","sequence":"first","affiliation":[{"name":"Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany"},{"name":"Fraunhofer Cluster of Excellence for Immune-Mediated Disease, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Tretbar","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany"},{"name":"Fraunhofer Cluster of Excellence for Immune-Mediated Disease, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Koehl","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany"},{"name":"Fraunhofer Cluster of Excellence for Immune-Mediated Disease, Leipzig, Germany"},{"name":"University of Leipzig Faculty of Medicine, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[{"name":"University Hospital Magdeburg, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Fricke","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany"},{"name":"Fraunhofer Cluster of Excellence for Immune-Mediated Disease, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"2025090312532647000_9.4.e002907.1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12395"},{"key":"2025090312532647000_9.4.e002907.2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrrheum.2017.7","article-title":"Haematopoietic stem cell transplantation for autoimmune diseases","volume":"13","author":"Swart","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2025090312532647000_9.4.e002907.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2"},{"key":"2025090312532647000_9.4.e002907.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3"},{"key":"2025090312532647000_9.4.e002907.5","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1016\/S2665-9913(20)30100-4","article-title":"Tolerance-inducing medicines in autoimmunity: rheumatology and beyond","volume":"2","author":"Stanway","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"2025090312532647000_9.4.e002907.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306"},{"key":"2025090312532647000_9.4.e002907.7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s42255-022-00537-5","article-title":"CAR-based therapies: opportunities for Immuno-medicine beyond cancer","volume":"4","author":"Aghajanian","year":"2022","journal-title":"Nat Metab"},{"key":"2025090312532647000_9.4.e002907.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0042-2"},{"key":"2025090312532647000_9.4.e002907.9","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2025090312532647000_9.4.e002907.10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025090312532647000_9.4.e002907.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725"},{"key":"2025090312532647000_9.4.e002907.12","doi-asserted-by":"crossref","unstructured":"Mackensen A , M\u00fcller F , Mougiakakos D , et al . Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022;28. doi:10.1038\/s41591-022-02091-9","DOI":"10.3410\/f.742323959.793595617"},{"key":"2025090312532647000_9.4.e002907.13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"The Lancet"},{"key":"2025090312532647000_9.4.e002907.14","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"2025090312532647000_9.4.e002907.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952"},{"key":"2025090312532647000_9.4.e002907.16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756"},{"key":"2025090312532647000_9.4.e002907.17","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2025090312532647000_9.4.e002907.18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197015","article-title":"Treg enhancing therapies to treat autoimmune diseases","volume":"21","author":"Eggenhuizen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025090312532647000_9.4.e002907.19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168415","article-title":"Tolerogenic dendritic cell-based approaches in autoimmunity","volume":"22","author":"Passeri","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025090312532647000_9.4.e002907.20","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1038\/d41586-021-01840-z","article-title":"Creating T cells to guard against autoimmune disease","volume":"595","author":"Bender","year":"2021","journal-title":"Nature"},{"key":"2025090312532647000_9.4.e002907.21","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.41"},{"key":"2025090312532647000_9.4.e002907.22","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAUT.2019.05.017"},{"key":"2025090312532647000_9.4.e002907.23","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/Foxp3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"2025090312532647000_9.4.e002907.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01959-0"},{"key":"2025090312532647000_9.4.e002907.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01960-7"},{"key":"2025090312532647000_9.4.e002907.26","doi-asserted-by":"crossref","first-page":"103057","DOI":"10.1016\/j.jaut.2023.103057","article-title":"Supraphysiological Foxp3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application","volume":"138","author":"Henschel","year":"2023","journal-title":"J Autoimmun"},{"key":"2025090312532647000_9.4.e002907.27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41434-022-00358-x","article-title":"Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation","volume":"30","author":"Proics","year":"2023","journal-title":"Gene Ther"},{"key":"2025090312532647000_9.4.e002907.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat Commun"},{"key":"2025090312532647000_9.4.e002907.29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2880"},{"key":"2025090312532647000_9.4.e002907.30","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594"},{"key":"2025090312532647000_9.4.e002907.31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1B\/2A study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"2025090312532647000_9.4.e002907.32","doi-asserted-by":"crossref","unstructured":"Doan A , Pulsipher MA . Hypogammaglobulinemia due to CAR T-cell therapy. Pediatr Blood Cancer 2018;65. doi:10.1002\/pbc.26914","DOI":"10.1002\/pbc.26914"},{"key":"2025090312532647000_9.4.e002907.33","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"2025090312532647000_9.4.e002907.34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.997482","article-title":"Treatment of aggressive T-cell lymphoma\/leukemia with anti-CD4 CAR T cells","volume":"13","author":"Feng","year":"2022","journal-title":"Front Immunol"},{"key":"2025090312532647000_9.4.e002907.35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12015-019-09876-5","article-title":"Targeting T cell malignancies using CD4Car T-cells and implementing a natural safety switch","volume":"15","author":"Ma","year":"2019","journal-title":"Stem Cell Rev Rep"},{"key":"2025090312532647000_9.4.e002907.36","doi-asserted-by":"crossref","first-page":"112783","DOI":"10.18632\/oncotarget.22626","article-title":"Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells","volume":"8","author":"Pinz","year":"2017","journal-title":"Oncotarget"},{"key":"2025090312532647000_9.4.e002907.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36379-2","article-title":"Prolonged experimental CD4+ T-cell depletion does not cause disease progression in SIV-infected African green monkeys","volume":"14","author":"Le Hingrat","year":"2023","journal-title":"Nat Commun"},{"key":"2025090312532647000_9.4.e002907.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1546-z"},{"key":"2025090312532647000_9.4.e002907.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2403-9"},{"key":"2025090312532647000_9.4.e002907.40","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"key":"2025090312532647000_9.4.e002907.41","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJMoa2301665","article-title":"Axicabtagene ciloleucel in large B-cell lymphoma. Reply","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"2025090312532647000_9.4.e002907.42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-Cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"2025090312532647000_9.4.e002907.43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR T cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat Commun"},{"key":"2025090312532647000_9.4.e002907.44","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ijc.33254","article-title":"Comments on \"cost of decentralized CAR T cell production in an academic non-profit setting\"","volume":"148","author":"Schmitt","year":"2021","journal-title":"Int J Cancer"},{"key":"2025090312532647000_9.4.e002907.45","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.33253","article-title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting","volume":"148","author":"Ran","year":"2021","journal-title":"Int J Cancer"},{"key":"2025090312532647000_9.4.e002907.46","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.33253","article-title":"Reply to: comments on \"cost of decentralized CAR T cell production in an academic non-profit setting","volume":"148","author":"Ran","year":"2021","journal-title":"Int J Cancer"},{"key":"2025090312532647000_9.4.e002907.47","doi-asserted-by":"crossref","first-page":"673","DOI":"10.18609\/cgti.2020.071","article-title":"The necessity of automated manufacture for cell-based immunotherapies: a cost-based analysis","volume":"6","author":"McCoy","year":"2020","journal-title":"Cell Gene Therapy Insights"},{"key":"2025090312532647000_9.4.e002907.48","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"2025090312532647000_9.4.e002907.49","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146268","article-title":"A first-in-human study of YTB323, a novel, Autologous CD19-directed CAR-T cell therapy manufactured using the novel T-charge TM platform, for the treatment of patients (Pts) with Relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"138","author":"Flinn","year":"2021","journal-title":"Blood"},{"key":"2025090312532647000_9.4.e002907.50","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146646","article-title":"Phase I study of Phe885, a fully human BCMA-directed CAR-T cell therapy for relapsed\/refractory multiple myeloma manufactured in <2 days using the T-charge TM platform","volume":"138","author":"Sperling","year":"2021","journal-title":"Blood"},{"key":"2025090312532647000_9.4.e002907.51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s44222-023-00031-x","article-title":"Optimizing the manufacturing and antitumour response of CAR T therapy","volume":"1","author":"Liu","year":"2023","journal-title":"Nat Rev Bioeng"},{"key":"2025090312532647000_9.4.e002907.52","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/d41586-020-02675-w","article-title":"Building better CAR-T therapies","volume":"585","author":"King","year":"2020","journal-title":"Nature"},{"key":"2025090312532647000_9.4.e002907.53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32334-5"},{"key":"2025090312532647000_9.4.e002907.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607"},{"key":"2025090312532647000_9.4.e002907.55","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-Gd2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat Med"},{"key":"2025090312532647000_9.4.e002907.56","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"key":"2025090312532647000_9.4.e002907.57","doi-asserted-by":"crossref","unstructured":"Mailankody S , Matous JV , Chhabra S , et al . Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med 2023;29. doi:10.1038\/s41591-023-02306-7","DOI":"10.1038\/s41591-022-02182-7"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:53:39Z","timestamp":1756929219000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,23]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/rmdopen-2022-002907"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002907","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}